Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009006 | 0.91 | RIPK1 (0.42) | RIPK1P2RX7EGFRKCNH2 | |
| SCHEMBL1506292 | 0.83 | RIPK1 (0.39) | RIPK1LMNAP2RX3SMN1; SMN2 | |
| SCHEMBL10009645 | 0.82 | MAPK1 (0.41) | RIPK1EGFR | |
| SCHEMBL1506343 | 0.81 | KDM4E (0.37) | RIPK1P2RX3EGFR | |
| SCHEMBL1506203 | 0.80 | RIPK1 (0.44) | RIPK1TP53P2RX3EGFRSMN1; SMN2 | |
| SCHEMBL1506153 | 0.77 | RIPK1 (0.39) | RIPK1P2RX7 | |
| SCHEMBL10008198 | 0.76 | GALR2 (0.43) | LMNAP2RX3SMN1; SMN2 | |
| SCHEMBL10011414 | 0.75 | KMT2A (0.40) | RIPK1P2RX7EGFR | |
| SCHEMBL1506045 | 0.74 | CYP1A2 (0.40) | RIPK1P2RX7EGFR | |
| SCHEMBL1506079 | 0.73 | IDO1 (0.41) | RIPK1P2RX7EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | RIPK1 2211/4885TP53 2419/4885P2RX7 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.